Alkermes plc.
Develops and commercializes medicines for central nervous system (CNS) diseases.
ALKS | US
Overview
Corporate Details
- ISIN(s):
- IE00B56GVS15 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- CONNAUGHT HOUSE, 0 DUBLIN 4
- Website:
- https://www.alkermes.com/
- Sector:
- Manufacturing
Description
Alkermes plc is a global biopharmaceutical company that develops and commercializes medicines for diseases of the central nervous system (CNS). The company's research and development efforts focus on complex psychiatric and neurological disorders. Its portfolio includes treatments for conditions such as schizophrenia, bipolar I disorder, alcohol dependence, and opioid dependence. Alkermes' clinical-stage pipeline features investigational therapies, including orexin 2 receptor agonists for sleep disorders like narcolepsy and idiopathic hypersomnia. The company's commercialized products include olanzapine and samidorphan, an oral atypical antipsychotic drug for adults with schizophrenia or bipolar I disorder.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Alkermes plc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Alkermes plc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Alkermes plc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
